SCHEMBL3628969

SCHEMBL3628969

COCCOCCOCCOCCOCCOCCOCCOCCCCCC(=O)O

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.76
TSHR P16473 6/20 0.50
LMNA P02545 2/20 0.50
NFKB1 P19838 1/20 0.50
PMP22 Q01453 1/20 0.50
GPR84 Q9NQS5 7/20 0.46
PPARG P37231 7/20 0.46
PPARD Q03181 7/20 0.46
PPARA Q07869 7/20 0.46
HDAC11 Q96DB2 5/20 0.46
PTPN1 P18031 3/20 0.46
TLR2 O60603 2/20 0.46
TDP1 Q9NUW8 2/20 0.46
FABP4 P15090 2/20 0.46
SLC22A6 Q4U2R8 1/20 0.46
SLC22A8 Q8TCC7 1/20 0.46
MEN1 O00255 1/20 0.46
ESR1 P03372 1/20 0.46
ALOX15 P16050 1/20 0.46
PDE4A P27815 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14010816 1.00 ALDH1A1 (0.76) ALDH1A1TSHRLMNANFKB1PMP22
SCHEMBL14010968 1.00 ALDH1A1 (0.76) ALDH1A1TSHRLMNANFKB1PMP22
SCHEMBL12906731 1.00 ALDH1A1 (0.76) ALDH1A1TSHRLMNANFKB1PMP22
SCHEMBL8262823 1.00 ALDH1A1 (0.76) ALDH1A1TSHRLMNANFKB1PMP22
SCHEMBL8269056 1.00 ALDH1A1 (0.76) ALDH1A1TSHRLMNANFKB1PMP22
SCHEMBL9007918 1.00 ALDH1A1 (0.76) ALDH1A1TSHRLMNANFKB1PMP22
SCHEMBL12592828 1.00 ALDH1A1 (0.76) ALDH1A1TSHRLMNANFKB1PMP22
SCHEMBL28550528 1.00 ALDH1A1 (0.76) ALDH1A1TSHRLMNANFKB1PMP22
SCHEMBL23191004 0.98 ALDH1A1 (0.72) ALDH1A1TSHRLMNANFKB1PMP22
SCHEMBL5351480 0.98 ALDH1A1 (0.72) ALDH1A1TSHRLMNANFKB1PMP22

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1613343-B1 INSULIN POLYPEPTIDE-OLIGOMER CONJUGATES, PROINSULIN POLYPEPTIDE-OLIGOMER CONJUGATES AND METHODS OF SYNTHESIZING SAME BIOCON LTD (IN) 2016-12-07 EP disclosed
EP-1404178-B1 MIXTURES OF INSULIN DRUG-OLIGOMER CONJUGATES COMPRISING POLYALKYLENE GLYCOL, USES THEREOF, AND METHODS OF MAKING SAME BIOCON LTD (IN) 2016-01-20 EP disclosed
EP-1404360-B1 MONODISPERSE MIXTURES OF CALCITONIN DRUG-OLIGOMER CONJUGATES COMPRISING POLYETHYLENE GLYCOL, USES THEREOF, AND METHODS OF MAKING SAME BIOCON LTD (IN) 2010-01-06 EP disclosed
US-20090281023-A9 Mixtures Of Calcitonin Drug-Oligomer Conjugates And Methods Of Use In Pain Treatment NOBEX CORPORATION (US) 2009-11-12 US disclosed
US-7611864-B2 Proinsulin polypeptide-oligomer conjugates BIOCON LIMITED (IN) 2009-11-03 US disclosed
EP-1430082-B1 METHODS OF SYNTHESIZING INSULIN POLYPEPTIDE-OLIGOMER CONJUGATES, AND PROINSULIN POLYPEPTIDE-OLIGOMER CONJUGATES AND METHODS OF SYNTHESIZING SAME BIOCON LTD (IN) 2009-10-28 EP disclosed
US-7470663-B2 Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same BIOCON LIMITED (IN) 2008-12-30 US disclosed
US-20080312135-A1 MIXTURES OF DRUG-OLIGOMER CONJUGATES COMPRISING POLYETHYLENE GLYCOL, USES THEREOF, AND METHODS OF MAKING SAME EKWURIBE NNOCHIRI N 2008-12-18 US disclosed
US-7368260-B2 Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same BIOCON LIMITED (IN) 2008-05-06 US disclosed
EP-1613343-A4 INSULIN POLYPEPTIDE-OLIGOMER CONJUGATES, PROINSULIN POLYPEPTIDE-OLIGOMER CONJUGATES AND METHODS OF SYNTHESIZING SAME BIOCON LTD (IN) 2008-03-05 EP disclosed
US-20030060606-A1 Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same BIOCON LIMITED (IN) 2003-03-27 US disclosed
WO-2003022210-A2 PHARMACEUTICAL COMPOSITIONS OF DRUG-OLIGOMER CONJUGATES AND METHODS OF TREATING DISEASES THEREWITH NOBEX CORPORATION (US) 2003-03-20 WO disclosed
WO-2003022996-A2 METHODS OF SYNTHESIZING INSULIN POLYPEPTIDE-OLIGOMER CONJUGATES, AND PROINSULIN POLYPEPTIDE-OLIGOMER CONJUGATES AND METHODS OF SYNTHESIZING SAME NOBEX CORPORATION (US) 2003-03-20 WO disclosed
WO-2003022208-A2 PHARMACEUTICAL COMPOSITIONS OF INSULIN DRUG-OLIGOMER CONJUGATES AND METHODS OF TREATING DISEASES THEREWITH NOBEX CORPORATION (US) 2003-03-20 WO disclosed
US-20030027995-A1 Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same BIOCON LIMITED (IN) 2003-02-06 US disclosed
US-20030027748-A1 Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same BIOCON LIMITED (IN) 2003-02-06 US disclosed
WO-2002098452-A1 MIXTURES OF GROWTH HORMONE DRUG-OLIGOMER CONJUGATES COMPROMISING POLYALKYLENE GLYCOL, USES THEREOF, AND METHODS OF MAKING SAME NOBEX CORPORATION (US) 2002-12-12 WO disclosed
WO-2002098446-A1 MIXTURES OF DRUG-OLIGOMER CONJUGATES COMPRISING POLYALKYLENE GLYCOL, USES THEREOF, AND METHODS OF MAKING SAME NOBEX CORPORATION (US) 2002-12-12 WO disclosed
WO-2002098451-A1 MIXTURES OF CALCITONIN DRUG-OLIGOMER CONJUGATES COMPRISING POLYALKYLENE GLYCOL, USES THEREOF, AND METHODS OF MAKING SAME NOBEX CORPORATION (US) 2002-12-12 WO disclosed
WO-2002098232-A1 MIXTURES OF INSULIN DRUG-OLIGOMER CONJUGATES COMPRISING POLYALKYLENE GLYCOL, USES THEREOF, AND METHODS OF MAKING SAME NOBEX CORPORATION (US) 2002-12-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281023-A9 Mixtures Of Calcitonin Drug-Oligomer Conjugates And Methods Of Use In Pain Treatment CALCB, CALCR, CALCA ALDH1A1 3849/4885TSHR 1949/4885LMNA 1468/4885
US-20030027748-A1 Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same IAPP, SI, IDE ALDH1A1 3570/4885TSHR 1412/4885LMNA 2643/4885
US-20030027995-A1 Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same GHRHR, GHSR, GHITM ALDH1A1 3621/4885TSHR 43/4885LMNA 3948/4885
US-20080312135-A1 MIXTURES OF DRUG-OLIGOMER CONJUGATES COMPRISING POLYETHYLENE GLYCOL, USES THEREOF, AND METHODS OF MAKING SAME SI, SLC10A2, FABP2 ALDH1A1 1943/4885TSHR 3744/4885LMNA 3331/4885
US-20030060606-A1 Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same CALCB, CALCR, CALCA ALDH1A1 3603/4885TSHR 1403/4885LMNA 1453/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.